Each year, Intouch sleuths South by Southwest, talking to experts, sharing insights, and getting inspired by the most creative minds in the world. On the ground, we debrief, connect the dots, and distill our findings to the themes and actions that will mean most to our teams and clients.
The Finance Committee of the U.S. Senate held two hearings – one in January and one in February -- on “Drug Pricing in America: A Prescription for Change.” As we’ve seen them unfold, they’ve been reminders of ongoing tensions with the industry, and a harbinger of what may be on the horizon for pharma manufacturers.
Fake news is everywhere — not just in the political realm. Accuracy is more important than ever, particularly with respect to conveying health information. How is your brand handling the challenge?
TL;DR: Authenticity is a popular 21st-century marketing buzzword. But when you pick apart what’s really behind that, you find new opportunities for pharma marketers. Authenticity, transparency, humanity, vulnerability – there are a lot of ways to describe what the public increasingly wants from brands. But simply put: they want
On November 20, 2018, the FDA published a Request for Comments about a proposed framework for regulating software applications (“apps”) disseminated by or on behalf of drug sponsors for use with one or more of their prescription drug products. This Intouch POV sets forth the scope of the proposed framework – what is and is not included, provides an overview of the proposed framework itself, and delivers recommendations for pharmaceutical companies involved in developing health-related apps.
As patients’ lives stretch for decades longer, a host of new considerations appear. What are your patients worried about for this new year… and for their years and decades ahead? Read on to learn about what questions to ask and how to help patients live better longer.
Patient support services programs have become common in the pharmaceutical industry, yet government scrutiny has left some pharma companies wondering what to do with these programs in the future. This POV lays out recommendations from overall business, compliance, legal, and regulatory viewpoints.
It’s been a little over a month since Digital Pharma East’s fall event in Philadelphia, but the takeaways haven’t expired. The conference was packed with insightful sessions; what follows are a few enduring lessons we wanted to share as we head into a new year, brimming with opportunities –
Copay accumulator programs have been a topic of great interest to a number of groups, including managed care organizations, biopharma manufacturers, and patients over the past year. There is no industry standard name for copay accumulators; e.g., UnitedHealthcare and Express Scripts use the terms “Coupon Adjustment: Benefit Plan Protection program”
The Department of Justice reaffirmed its longstanding policy that Title III of the Americans with Disabilities Act (ADA) applies to websites, though once again, it declined to issue specific regulations on what websites need to do to comply with the law. In this POV from our user experience expert, Amy Toft, we explain the importance of accessibility, how adherence to Title III affects websites, and how making content accessible to all users affects pharma.
